ArticleClinics (Sao Paulo, Brazil)2008
Identification of growth hormone receptor in plexiform neurofibromas of patients with neurofibromatosis type 1.
Article in Clinics (Sao Paulo, Brazil), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Neurofibromatosis Type 1 Presenting With a Mesenteric Plexiform Neurofibroma and Epididymitis.Cureus · 2026Article
- Brachial plexus peripheral nerve sheath tumors (PNSTs): clinical and surgical management in the pediatric population.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024Article
- Turner Syndrome and Neurofibromatosis 1: Rare Co-Existence with Important Clinical Implications.Journal of the ASEAN Federation of Endocrine Societies · 2023Article
- Head circumference and anthropometric changes and their relation to plexiform and skin neurofibromas in sporadic and familial neurofibromatosis 1 Brazilian adults: a cross-sectional study.Orphanet journal of rare diseases · 2022Article
- Partial empty sella syndrome, GH deficiency and transient central adrenal insufficiency in a patient with NF1.Endocrine · 2020Article
- Management of cutaneous neurofibroma: current therapy and future directions.Neuro-oncology advances · 2020Review
- Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966.Orphanet journal of rare diseases · 2020Article
- Receptor of ghrelin is expressed in cutaneous neurofibromas of individuals with neurofibromatosis 1.Orphanet journal of rare diseases · 2017Article
- Rare Presentation of Neurofibromatosis and Turner Syndrome in a Pediatric Patient.Pediatric reports · 2017Article
- Initial Exploration on Temporal Branch of Facial Nerve Function Preservation in Plexiform Neurofibroma Resection.The Journal of craniofacial surgery · 2016Article
- Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee.The Journal of clinical endocrinology and metabolism · 2015Review
- Validity and interexaminer reliability of a new method to quantify skin neurofibromas of neurofibromatosis 1 using paper frames.Orphanet journal of rare diseases · 2014Article
- Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.PloS one · 2014Article
- Malignant peripheral nerve sheath tumors: clinicopathological aspects, expression of p53 and survival.Clinics (Sao Paulo, Brazil) · 2012Article
- Analysis of steroid hormone effects on xenografted human NF1 tumor schwann cells.Cancer biology & therapy · 2010Article
- Neurofibromatosis with unilateral lower limb gigantism.Musculoskeletal surgery · 2010Article
- Propranolol Specifically Suppresses the Viability of Tumorous Schwann Cells Derived from Plexiform NeurofibromasIn vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to investigate the presence of growth hormone receptor in plexiform neurofibromas of neurofibromatosis type 1 patients.
introductionThe development of multiple neurofibromas is one of the major features of neurofibromatosis type 1. Since neurofibromas commonly grow during periods of hormonal change, especially during puberty and pregnancy, it has been suggested that hormones may influence neurofibromatosis type 1 neurofibromas. A recent study showed that the majority of localized neurofibromas from neurofibromatosis type 1 patients have growth hormone receptor.
methodsGrowth hormone receptor expression was investigated in 5 plexiform neurofibromas using immunohistochemistry.
resultsFour of the 5 plexiform neurofibromas were immunopositive for growth hormone receptor.
conclusionThis study suggests that growth hormone may influence the development of plexiform neurofibromas in patients with neurofibromatosis type 1.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.